Statins and their role in pre-percutaneous coronary intervention

Current Cardiology Reports

Volumn 12, Issue 4, 2010, Pages 295-301

  Melfi, Rosetta ^a   Nusca, Annunziata ^a   Patti, Giuseppe ^a   Di Sciascio, Germano ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Acute coronary syndrome; Chronic angina; Myocardial infarction; Percutaneous coronary intervention; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE MB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EARLY INTERVENTION; HEART ARREST; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; REVIEW; RISK REDUCTION; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CONTRAST MEDIA; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MYOCARDIAL INFARCTION; PREOPERATIVE CARE; RISK FACTORS; TIME FACTORS;

EID: 77956392118     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0110-0     Document Type: Review

References (47)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S) [no authors listed]. Lancet 1994, 344:1383-1389.
2. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Heart Protection Study Investigators [no authors listed]. Lancet 2002, 360:7-22.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group [no authors listed]. N Engl J Med 1998, 339:1349-1357.
4. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:39-43.
5. Morikawa S, Takabe W, Mataki C, et al.: The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002, 9:178-183.
6. Abdelmeguid AE, Topol EJ, Whitlow PL, et al.: Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions. Circulation 1996, 94:1528-1536.
7. Brener SJ, Ellis SG, Schneider J, Topol EJ: Frequency and longterm impact of myonecrosis after coronary stenting. Eur Heart J 2002, 23:869-876.
8. Thygesen K, Alpert JS, White HD, et al.: Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
9. Ioannidis JP, Karvouni E, Katritis DG: Mortality risk conferred by small elevations of creatinine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 2003, 42:1406-1411.
10. Turer AT, Mahaffey KW, Gallup D, et al.: Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med 2005, 6:12-15.
11. Kurz DJ, Naegeli B, Bertel O: A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J 2000, 139:35-43.
12. Wang FW, Osman A, Otero J, et al.: Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003, 107:2914-2919.
13. Randomised placebo-controlled and balloon-angioplastycontrolled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators [no authors listed]. Lancet 1998, 352:87-92.
14. Desmet WJ, Dens J, Coussement P, Van de Werf F: Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. Heart 2002, 88:293-295.
15. Gruberg L, Mintz GS, Mehran R, et al.: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36:1542-1548.
16. Rihal CS, Textor SC, Grill DE, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264.
17. Lindsay J, Apple S, Pinnow EE, et al.: Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatine. Catheter Cardiovasc Interv 2003, 59:338-343.
18. Herrmann J, Lerman A, Baumgart D, et al.: Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002, 106:2180-2183.
19. Chan AW, Bhatt DL, Chew DP, et al.: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002, 105:691-696.
20. Chan AW, Bhatt DL, Chew DP, et al.: Relation of inflammation and benefit of statins after percutaneous intervention on frequency of periprocedural myocardial injury. Am J Cardiol 2004, 94:1363-1366.
21. Pasceri V, Patti G, Nusca A, et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004, 110:674-678.
22. Pasceri V, Chang JS, Willerson JT, et al.: Modulation of Creactive protein-mediated monocyte chemoattractant protein-1 induction in endothelial cells by anti-atherosclerotic drugs. Circulation 2001, 103:2531-2534.
23. Albert MA, Danielson E, Rifai N, et al.: Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286:64-70.
24. Chan AW, Bhatt DL, Chew DP, et al.: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003, 107:1750-1756.
25. Patti G, Di Sciascio G, D'Ambrosio A, et al.: Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002, 89:372-376.
26. Walter DH, Fichtlscherer S, Sellwig M, et al.: Preprocedural Creactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001, 37:839-846.
27. Jones SP, Lefer DJ: Cardioprotective action of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001, 173:139-143.
28. Notarbartolo A, Davi G, Averna M, et al.: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:247-251.
29. Sanguigni V, Pignatelli P, Lenti L, et al.: Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005, 111:412-419.
30. Kinlay S, Schwartz GG, Olsson AG, et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560-1566.
31. Patti G, Chello M, Pasceri V, et al.: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: Results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006, 48:1560-1566.
32. Gatto L, Patti G, Chello M, et al.: Procedural myocardial protection by short-term atorvastatin load is related to lower levels of adhesion molecules after PCI in patients with ACS. results from the ARMYDA-ACS CAMs substudy. Giornale Italiano di Cardiologia 2009, 10:159 S.
33. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention \no authors listed]. Eur Heart J 1998, 19:1434-1503.
34. Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008, 52:2046-2099.
35. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. JAMA 2001, 285:1711-1718.
36. Briel M, Schwartz GG, Thompson PL, et al.: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: A meta-analysis of randomized controlled trials. JAMA 2006, 295:2046-2056.
37. Hulten E, Jackson JL, Douglas K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: A metaanalysis of randomized controlled trials. Arch Intern Med 2006, 166:1814-1821.
38. Bavry AA, Mood GR, Kumbhani DJ, et al.: Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: A systematic review of randomized trials. Am J Cardiovasc Drugs 2007, 7:135-141.
39. Chang SM, Yazbek N, Lakkis NM: Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Cathet Cardiovasc Interv 2004, 62:193-197.
40. Patti G, Pasceri V, Colonna G, et al.: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49:1272-1278. Patients with ACS, treated early with PCI and statin pretreatment, could have an adjunctive beneficial effect on clinical outcome.
41. Di Sciascio G, Patti G, Pasceri V, et al.: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 2009, 54:558-565. The majority of patients with coronary artery disease are on chronic therapy with statins; in this group of patients, a high-dose reloading of statins has advantages in terms of MACE at follow-up.
42. Murphy SW, Barrett BJ, Parfrey PS: Contrast nephropathy. J Am Soc Nephrol 2000, 11:177-182.
43. Khanal S, Attallah N, Smith DE, et al.: Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med 2005, 118:843-849.
44. Patti G, Nusca A, Chello M, et al.: Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008, 101:279-285.
45. Ichiki T, Takeda K, Tokunou T, et al.: Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001, 21:1896-1901.
46. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, et al.: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101:2711-2719.
47. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003, 24:225-248.